Dermavant Sciences→Organon
Acquisition · Cash + milestone payments · OGN · announced Sep 18, 2024
Announced
Sep 18, 2024
Closed
Dec 31, 2024
Economics
Cash + milestone payments()
Pre-deal · pre-deal mark: 2024, year precision · rounding grid ±$100M · Organon press release — Dermavant Sciences acquisition, 2024
$175M upfront + $75M near-term milestone + $950M commercial milestones = up to $1.2B total
Target
Dermavant Sciences
Dermatology · Clinical / therapeutic
HQ Basel, Switzerland · Founded 2016
Immuno-dermatology subsidiary of Roivant; VTAMA cream for plaque psoriasis and atopic dermatitis — women disproportionately affected
- Organon press release (September 18, 2024)
- Fierce Pharma coverage (September 18, 2024)
- Roivant/Dermavant investor presentation (September 2024)
Acquirer
Organon (OGN)
Reproductive Health
HQ Jersey City, NJ
Why this buyer
Curated copy from the verified dataset — not an 8-K LLM summary
Extended Organon's women's health portfolio to US dermatology with VTAMA cream; psoriasis and atopic dermatitis disproportionately affect women
Evidence ladder
Secondary (press / IR)
Organon press release (September 18, 2024)
Secondary (press / IR)
Fierce Pharma
Primary (regulatory / filing)
SEC EDGAR 8-K https://www.sec.gov/Archives/edgar/data/1821825/000110465924102053/tm2424316d1_8k.htm
Open source
Limitations
- $175M upfront + $75M near-term milestone + $950M commercial milestones = up to $1.2B total
- Pre-deal valuation sourced from: Organon press release — Dermavant Sciences acquisition, 2024. Pre-deal market-cap and funding citations do not corroborate the acquisition.
Other verified deals by Organon
Acquirer program history not already listed as a valuation peer or adjacency row.
| Target | Acquirer | Announced | Value | Sector |
|---|---|---|---|---|
| Forendo Pharma | Organon | Nov 11, 2021 | Reproductive Health | |
| Alydia Health | Organon (via Merck spinoff) | Mar 30, 2021 | Maternal Health |
Patient empowerment context
Patient empowerment baseline (HLTH 2022)
No curated mapping — Dermavant Sciences (Dermatology). HLTH/Outcomes4Me 2022 baseline is Breast cancer care continuum (HLTH 2022). No curated mapping for this target in the verified crosswalk.
Research workspace (includes heuristic crosswalk) →Related verified workspaces
Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.
Curated verified dataset v9 · updated 2026-09-20 · 3 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.